Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Inclusion Criteria: * Target population is unresectable stage III non-small cell lung cancer. * Written informed consent provided. * Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene. * Male and female patients aged ≥18 years, \< 75 years. * Able to comply with the required protocol and follow-up procedures, and able to receive oral medications. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Life expectancy ≥12 weeks. * Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level). * Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases. * Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min. * Female subjects should not be pregnant or breast-feeding. Exclusion Criteria: * Known severe hypersensitivity to IBI308 or any of the excipients of this product. * Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). * Prior chemotherapy or radiotherapy. * Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur …